We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02171260
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : February 2, 2018
Information provided by (Responsible Party):
Eisai Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : May 5, 2017
  Study Completion Date : December 22, 2017